肺癌
医学
重症监护医学
临床试验
癌症
精密医学
肺癌筛查
工作队
药物开发
梅德林
肺癌的治疗
医学物理学
转化研究
分析
抗癌药物
抗药性
任务(项目管理)
肿瘤科
癌症生物标志物
生物信息学
药品
临床研究
食品药品监督管理局
癌症治疗
靶向治疗
作者
Monte M. Winslow,Mohamed A. Ahmed,Christine D. Berg,James R. Black,J Downward,Ramaswamy Govindan,Roy S. Herbst,John V. Heymach,Elizabeth M. Jaffee,Norbert Kraut,Miriam Merad,M. Meyerson,Tej Pandya,Katerina Politi,Arati V. Rao,Charles M. Rudin,Jean Charles Soria,Yuning J. Tang,Kwok-Kin Wong,Timothy A. Yap
标识
DOI:10.1158/2159-8290.cd-25-2318
摘要
Advances in targeted therapies, immunotherapy, and early detection have revolutionized lung cancer treatment and extended survival. Nonetheless, lung cancer remains highly fatal. Here, we identify knowledge gaps and propose critical areas of future research, aligning with the mission of the AACR Lung Cancer Task Force. We delineate research priorities, including advancing prevention initiatives, enhancing early detection strategies, developing novel treatments, and refining patient stratification. Addressing disparities and increasing efforts on relatively neglected lung cancer subtypes are also essential. Finally, international collaboration, centralized clinical trial databases, novel clinical trial designs, and artificial intelligence-driven analytics should accelerate precision medicine and aid in elucidating drug resistance mechanisms. Together, these efforts promise to improve patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI